ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wagner, M.
Right arrow Articles by Mark, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wagner, M.
Right arrow Articles by Mark, M.
Annals of Clinical and Laboratory Science, Vol 26, Issue 5, 389-395
Copyright © 1996 by Association of Clinical Scientists


Articles

Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease

ML Wagner, MN Fedak, JI Sage, and MH Mark

The incidence of complications associated with disease and treatment was compared in younger versus elderly patients with Parkinson's disease (PD). One hundred sixty-five patient records were divided according to patient age into two groups ("younger," 41 to 64, and "elderly," > or = 65 years) and reviewed for the incidence of dyskinesias, fluctuations, freezing, psychosis, dementia, depression, and insomnia. Younger patients had a greater incidence of chorea (75.8 percent vs 49.5 percent), dystonia (82.3 percent vs 49.0 percent), fluctuations (90.1 percent vs 68.1 percent), depression (73.2 percent vs 36.8 percent), and insomnia (57.9 percent vs 18.1 percent). There were no significant differences in the incidence of freezing, dementia, or psychosis. At the time of the first adverse event, there was no difference in patient characteristics such as gender, lag time from disease diagnosis to levodopa initiation, disease symptoms at the time of diagnosis, levodopa dose, or concomitant drug use despite the fact that the older group had a longer duration of disease, higher Hoehn and Yahr stage, an older age at onset of PD, and longer duration of levodopa use. Younger patients with PD experience a greater incidence of adverse effects than do elderly PD patients. The spectrum of adverse effects is comparable to those of young-onset (< or = 40 years) patients.


This article has been cited by other articles:


Home page
Arch NeurolHome page
J. Jankovic and A. S. Kapadia
Functional Decline in Parkinson Disease
Arch Neurol, October 1, 2001; 58(10): 1611 - 1615.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
G K Wenning, Y Ben-Shlomo, A Hughes, S E Daniel, A Lees, and N P Quinn
What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease?
J. Neurol. Neurosurg. Psychiatry, April 1, 2000; 68(4): 434 - 440.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
S. Fahn
Parkinson Disease, the Effect of Levodopa, and the ELLDOPA Trial
Arch Neurol, May 1, 1999; 56(5): 529 - 535.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the Association of Clinical Scientists.